JP2007504213A5 - - Google Patents

Download PDF

Info

Publication number
JP2007504213A5
JP2007504213A5 JP2006525215A JP2006525215A JP2007504213A5 JP 2007504213 A5 JP2007504213 A5 JP 2007504213A5 JP 2006525215 A JP2006525215 A JP 2006525215A JP 2006525215 A JP2006525215 A JP 2006525215A JP 2007504213 A5 JP2007504213 A5 JP 2007504213A5
Authority
JP
Japan
Prior art keywords
glutaminyl
use according
pharmaceutically acceptable
acceptable salt
thiazolidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006525215A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007504213A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2004/003082 external-priority patent/WO2005020983A2/en
Publication of JP2007504213A publication Critical patent/JP2007504213A/ja
Publication of JP2007504213A5 publication Critical patent/JP2007504213A5/ja
Withdrawn legal-status Critical Current

Links

JP2006525215A 2003-09-02 2004-09-02 糖血症コントロールの処置のための併用療法 Withdrawn JP2007504213A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49953503P 2003-09-02 2003-09-02
PCT/IB2004/003082 WO2005020983A2 (en) 2003-09-02 2004-09-02 Combination therapy for glycaemic control

Publications (2)

Publication Number Publication Date
JP2007504213A JP2007504213A (ja) 2007-03-01
JP2007504213A5 true JP2007504213A5 (https=) 2007-08-30

Family

ID=34272835

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006525215A Withdrawn JP2007504213A (ja) 2003-09-02 2004-09-02 糖血症コントロールの処置のための併用療法

Country Status (14)

Country Link
US (1) US20060287251A1 (https=)
EP (1) EP1663200A2 (https=)
JP (1) JP2007504213A (https=)
KR (1) KR20060119927A (https=)
CN (1) CN1845731A (https=)
AU (1) AU2004267955A1 (https=)
BR (1) BRPI0413204A (https=)
CA (1) CA2536432A1 (https=)
EA (1) EA200600356A1 (https=)
IL (1) IL173844A0 (https=)
MX (1) MXPA06002127A (https=)
NO (1) NO20061085L (https=)
WO (1) WO2005020983A2 (https=)
ZA (1) ZA200601770B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0526291D0 (en) * 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
FR2896157B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
GB0623892D0 (en) * 2006-11-29 2007-01-10 Medical Res Council Technology Assay
EP2552952A1 (en) * 2010-03-26 2013-02-06 Novo Nordisk A/S Novel glucagon analogues
MX359329B (es) * 2011-10-28 2018-09-25 Sanofi Aventis Deutschland Una combinación farmacéutica para usarse en el tratamiento de un paciente que padece diabetes tipo 2.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19823831A1 (de) * 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE29924609U1 (de) * 1999-05-28 2004-04-22 Probiodrug Ag Neue Effektoren von Dipeptidylpeptidase IV
PT1741446E (pt) * 2000-01-21 2008-05-09 Novartis Pharma Ag Combinações incluindo inibidores da dipeptidilpeptidase-iv e agentes anti-diabéticos
US6890905B2 (en) * 2001-04-02 2005-05-10 Prosidion Limited Methods for improving islet signaling in diabetes mellitus and for its prevention
JP2005527504A (ja) * 2002-02-28 2005-09-15 プロシディオン・リミテッド グルタミニルを基礎するdpiv阻害剤
WO2004031374A2 (en) * 2002-09-18 2004-04-15 Prosidion Ltd. Secondary binding site of dipeptidyl peptidase iv (dp iv)

Similar Documents

Publication Publication Date Title
TWI241185B (en) Antidiabetic formulation
KR100643833B1 (ko) 인슐린 감작제 및 다른 항당뇨병 약제의 개선된 방출을위한 제약 조성물
JP2009520801A5 (https=)
Setter et al. Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy
JP5072848B2 (ja) 低血糖イベントを低減するためのdpp−iv阻害剤の使用
JP2016501841A5 (https=)
JP2008517921A5 (https=)
JP2013227337A (ja) Dpivインヒビターおよびメトホルミンまたはチアゾリジンジオンの組み合わせによる2型糖尿病の治療
JP2006515267A5 (https=)
US6780432B1 (en) Core formulation
JP2010540667A5 (https=)
JP2008517921A (ja) Dpp−iv阻害剤、ppar抗糖尿病薬およびメトホルミンの組合わせ剤
AU2007293885A1 (en) Combination treatment for diabetes mellitus
US6296874B1 (en) Core formulation comprising troglitazone and abiguanide
Kiayias et al. Rosiglitazone in combination with glimepiride plus metformin in type 2 diabetic patients
JP2007504213A5 (https=)
US20030224046A1 (en) Unit-dose combination composition for the simultaneous delivery of a short-acting and a long-acting oral hypoglycemic agent
US6461639B2 (en) Core formulation
MXPA06001629A (es) Composicion nueva que comprende rosiglitazona y otro agente antidiabetico.
AU2001257456B2 (en) A core formulation
JPWO2020194046A5 (https=)
JP2004536841A (ja) コア製剤
AU2001257456A1 (en) A core formulation
Jeong et al. The effect of the taeguk gi-gong exercise on insulin resistance and blood glucose in patients with type II diabetes mellitus
TW202015683A (zh) Glp1r激動劑的治療用途